

**DCF Psychotropic Medication Advisory Committee
Meeting Notes**

October 5, 2012 1:00PM

Solnit Center for Children, Middletown, CT.

Present: Allen Alton, MD; David Aresco, RPh; Jason Gott, RPh; Chris Malinowski, APRN; Beth Muller, APRN; Joan Narad, M.D.; Laurei Vander Heide, PhD; Amy Veivia, Pharm.D.; Marissa Ragonesi, Pharm.D. Candidate Uconn; Daniel Rocki, Pharm.D. Candidate UConn; Julie Flood, APRN Candidate Fairfield University.

1. Call to order: Chris Malinowski called the meeting to order at 110pm.
2. Set date/time of next meeting: The next meeting is scheduled for November 2, 2012 from 1pm – 2:30pm; Solnit Center AB conference room.
3. Minutes of the September 2012 meeting were reviewed and approved.
4. Announcements: Marissa Ragonesi and Daniel Rocki (Pharm.D. candidates, UConn School of Pharmacy) were introduced to the members.
5. New Business:
 - Approved drug list additions for consideration: see monograph for each medication being evaluated.
 - Cymbalta: monograph reviewed and discussed. CMCU role in the approval of this drug when used for fibromyalgia was discussed. The various side effects were discussed. The combination of Lyrica, Cymbalta, and gabapentin was discussed. Noted there are no evidenced based clinical trials involving children/adolescents for this medication. The committee voted to NOT approve this medication for addition to the approved drug list until such time as data related to use in children/adolescents becomes available.
 - Latuda; monograph reviewed and discussed. Noted suggest max daily dose is 160mg. Noted there are currently evidenced based clinical trials underway involving children/adolescents for this medication. The committee voted to NOT approve this medication for addition to the approved drug list until such time as data related to use in children/adolescents becomes available.
 - Viibryd; monograph reviewed and discussed. Noted there are currently evidenced based clinical trials underway involving children/adolescents for this medication. The committee voted to NOT approve this medication for addition to the approved

drug list until such time as data related to use in children/adolescents becomes available.

- Drug Use Guidelines: recommended changes based on full review.
 - A report showing recommended changes based on a full review was distributed and discussed.
 - The Committee decided to defer discussion of and recommendations for changes to the Drug Use Guidelines to the November 2012 meeting.
 - Maximum dose guideline: recommended changes based on full review.
 - Defer to the November 2012 meeting.
6. Drug Information Inquiries (April 2012 – September 2012)
- From DI phone line: Defer to the November 2012 meeting.
 - From PMAC: Defer to the November 2012 meeting.
7. Other. Connecticut BHP Pharmacy Utilization Report: Presented by Laurie Vander Heide:
- A report detailing Psychotropic Medication use from 2008 – 2011 was distributed and presented by Laurie Vander Heide. There was much discussion regarding the report to include:
- Noted it is difficult to tease out data for committed vs. involved children.
 - Noted that the #'s in the graph depicted on page 11 may be skewed to show high utilization by DCF involved children/adolescents.
 - It was noted that stimulant use in adults rose from 4.7% to 7.6% in the period 2008 – 2011.
 - Noted that antipsychotic use in children and youth decreased from 30.5% to 24.8% over the period 2008 – 2011. (Note denominator is children/youth on behavioral medications).
 - The use of diphenhydramine (Benadryl) was discussed. The committee made a recommendation to break out utilization of this medication in the report.
 - Noted that page 17 shows a decrease in the use of antipsychotic agents in DCF youth (over 60% to just over 50%) from 2010 to 2011.
 - The summary on page 24 was reviewed and discussed.
8. Adjournment: the meeting was adjourned at 240pm.

Respectfully submitted:

David S. Aresco, RPh, FASCP